...
首页> 外文期刊>Molecular and Cellular Biochemistry: An International Journal for Chemical Biology >Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis.
【24h】

Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis.

机译:肝细胞癌中SOCS2和SOCS6表达的减少与侵袭性肿瘤进展和不良预后相关。

获取原文
获取原文并翻译 | 示例

摘要

To investigate the clinical significance of suppressor of cytokine signaling (SOCS)-2 and SOCS6 in human hepatocellular carcinoma (HCC). The expression levels of SOCS2 and SOCS6 mRNA and protein in tumor, para-tumor and normal liver tissues were detected in 106 HCC patients by real-time quantitative RT-PCR (qRT-PCR) and Western blot. According to qRT-PCR and western blot analyses, we first found that both the expression levels of SOCS2 and SOCS6 mRNA and protein in HCC were significantly lower than those in para-tumor (both P < 0.001) and normal liver tissues (both P < 0.001). Then, the correlation analysis showed that both SOCS2 and SOCS6 protein downregulation were significantly correlated with advanced TNM stage (both P < 0.001) and high serum AFP (P = 0.008 and 0.01, respectively). Especially, the reduced expression of SOCS2 more frequently occurred in HCC patients with vascular invasion (P = 0.03), and that of SOCS6 was also associated with tumor recurrence (P = 0.01). Moreover, HCC patients with low expression of SOCS2 and SOCS6 had significantly shorter overall (P = 0.008 and 0.01, respectively) and disease-free survival (both P = 0.01). Furthermore, multivariate analysis showed that both SOCS2 and SOCS6 downregulation were independent prognostic factors of overall (P = 0.01 and 0.03, respectively) and disease-free survival (P = 0.01 and 0.03, respectively) in HCC. Our data demonstrate for the first time that SOCS2 and SOCS6 expression were remarkably reduced in HCC and may be served as potential prognostic markers for patients with this deadly disease.
机译:目的探讨人肝细胞癌(HCC)中细胞因子信号转导(SOCS)-2和SOCS6抑制剂的临床意义。采用实时定量RT-PCR和蛋白质印迹法检测106例HCC患者肿瘤,癌旁组织和正常肝组织中SOCS2和SOCS6 mRNA及蛋白的表达水平。根据qRT-PCR和Western blot分析,我们首先发现HCC中SOCS2和SOCS6 mRNA和蛋白的表达水平均显着低于癌旁(均P <0.001)和正常肝组织(均P < 0.001)。然后,相关分析表明,SOCS2和SOCS6蛋白的下调均与晚期TNM分期(均P <0.001)和高血清AFP显着相关(分别为P = 0.008和0.01)。特别是,在血管侵犯的HCC患者中,SOCS2的表达降低更为常见(P = 0.03),而SOCS6的表达​​也与肿瘤复发相关(P = 0.01)。而且,SOCS2和SOCS6低表达的HCC患者的总体总体生存时间明显缩短(分别为P = 0.008和0.01),无病生存期(均为P = 0.01)。此外,多因素分析表明,SOCS2和SOCS6的下调都是肝癌总体(P = 0.01和0.03)和无病生存(P = 0.01和0.03)的独立预后因素。我们的数据首次证明SOCS2和SOCS6表达在肝癌中显着降低,并且可以作为这种致命疾病患者的潜在预后标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号